

STUDY PROTOCOL

Open Access

Multifamily Group Psychoeducation and Cognitive Remediation for First-Episode Psychosis: A Randomized Controlled Trial

Nicholas JK Breitborde^{1,2*}, Francisco A Moreno^{1,2}, Natalie Mai-Dixon³, Rachele Peterson¹, Linda Durst^{1,2}, Beth Bernstein^{1,2}, Seenayah Byreddy¹, William R McFarlane⁴

Abstract

Background: Multifamily group psychoeducation (MFG) has been shown to reduce relapse rates among individuals with first-episode psychosis. However, given the cognitive demands associated with participating in this intervention (e.g., learning and applying a structured problem-solving activity), the cognitive deficits that accompany psychotic disorders may limit the ability of certain individuals to benefit from this intervention. Thus, the goal of this study is to examine whether individuals with first-episode psychosis who participate simultaneously in MFG and cognitive remediation—an intervention shown to improve cognitive functioning among individuals with psychotic disorders—will be less likely to experience a relapse than individuals who participate in MFG alone.

Methods/Design: Forty individuals with first-episode psychosis and their caregiving relative will be recruited to participate in this study. Individuals with first-episode psychosis will be randomized to one of two conditions: (i) MFG with concurrent participation in cognitive remediation or (ii) MFG alone. The primary outcome for this study is relapse of psychotic symptoms. We will also examine secondary outcomes among both individuals with first-episode psychosis (i.e., social and vocational functioning, health-related quality of life, service utilization, independent living status, and cognitive functioning) and their caregiving relatives (i.e., caregiver burden, anxiety, and depression)

Discussion: Cognitive remediation offers the possibility of ameliorating a specific deficit (i.e., deficits in cognitive functioning) that often accompanies psychotic symptoms and may restrict the magnitude of the clinical benefits derived from MFG.

Trial Registration: ClinicalTrials (NCT): NCT01196286

Background

There is growing evidence that the majority of the psychosocial deterioration that accompanies psychotic disorders occurs during the first few years of illness [1-3] and that the prevention or delay of early deterioration may be associated with a better course of illness [4-7]. One intervention which has been shown to be particularly effective in the treatment of psychotic disorders is family psychoeducation—an umbrella term for a group of interventions that provide families with education

about psychotic disorders and strategies to improve problem-solving skills and communication within the family [8]. To date, multiple studies have demonstrated that the receipt of family psychoeducation is associated with lower rates of relapse among individuals with psychotic disorders [9,10] with individuals with first-episode psychosis experiencing greater clinical benefits than individuals later in the course of a psychotic disorder [11,12].

One particular form of family psychoeducation which has shown promise among individuals with first-episode psychosis is multifamily group psychoeducation (MFG) [11]. This intervention provides participants with information about the course and treatment of psychotic disorders and trains participants in the use of a structured

* Correspondence: breitbor@email.arizona.edu

¹Department of Psychiatry, University of Arizona, 1501 N. Campbell Ave., PO Box 245002, Tucson, AZ, 85724-5002, USA

Full list of author information is available at the end of the article

problem-solving exercise designed to help them navigate the many challenges associated with living with a psychotic disorder or caring for a relative with a psychotic disorder. Among individuals with psychotic disorders, participation in MFG is associated with reduced rates of relapse [13,14], and the clinical benefit of this intervention appears to be greater among individuals with first-episode psychosis as opposed to individuals with a chronic psychotic disorder [11]. The success of this intervention among individuals with first-episode psychosis has led to the incorporation of MFG within several major international studies of first-episode psychosis (e.g., OPUS [15] and TIPS [16]).

However, like all psychosocial interventions, some individuals who participate in MFG will still experience negative health outcomes. With regard to individuals with first-episode psychosis, approximately 20% may experience a symptomatic relapse and 50% may be hospitalized over a two-year period despite participating in family psychoeducation [11,13]. Thus, despite the clear clinical benefits associated with participation in MFG, there is still room for improvement with regard to the clinical outcomes of individuals who participate in this intervention.

One factor that may limit the benefit of psychosocial treatments (e.g., MFG) for psychosis is the cognitive deficits that tend to accompany psychotic disorders [17,18]. Cognitive deficits in areas such as problem-solving ability, verbal memory, and attention are common in individuals with psychotic disorders [19,20] (including those early in the course of a psychotic disorder [21,22]) and have been recognized as a “rate-limiting” factor which may hinder individuals’ ability to learn and execute new skills [18,23]. In the context of MFG, these cognitive deficits may hinder an individual’s ability to learn and participate in the problem-solving activity which is the hallmark of MFG. Addressing these cognitive deficits, in particular those related to problem-solving, could potentially facilitate greater participation and understanding of the MFG problem-solving activity among individuals with first-episode psychosis—thereby facilitating greater clinical benefits associated with participation in this intervention.

Recently, greater attention has been directed toward the development of strategies to ameliorate the cognitive deficits that accompany psychotic disorders. One strategy which has been shown to be successful in this endeavor is cognitive remediation (CR). This intervention, which is recognized as a “best practice” in the treatment of psychotic disorders [24,25], is typically comprised of a series of repeated exercises delivered by a clinician or via a computer that are designed to improve performance in cognitive functioning. A recent meta-analysis has shown that participation in cognitive

remediation programs is associated with improvements in multiple domains of cognitive functioning, including problem-solving ability [26]. The success of CR in improving problem-solving skills (and other areas of cognitive functioning) raises the possibility that individuals with first-episode psychosis who participate concurrently in MFG and CR may be better able to learn and apply the problem-solving activity completed during MFG sessions. This, in turn, could lead to improvements in outcomes experienced by these individuals.

Thus, the goal of this study is to examine whether concurrent participation in MFG and CR is associated with better outcomes among individuals with first-episode psychosis than participation in MFG alone. We hypothesize that relapse rates will be lower among individuals who participate in the MFG and CR condition as opposed to MFG alone. However, recognizing that the benefits of MFG and CR may not be limited to relapse alone, we will also examine the benefits of these interventions with regard to secondary outcome measures for both individuals with first-episode psychosis and their caregiving relatives.

Methods/Design

This project was approved University of Arizona Human Subjects Protection Program.

Participants

Sample Characteristics

Individuals with first-episode psychosis and their caregiving relatives will be recruited from the Early Psychosis Intervention Center (EPICENTER) at University Physicians Hospital. EPICENTER is an outpatient treatment program that provides evidence-based psychosocial treatments for individuals experiencing their first psychotic episode. Inclusion criteria for participants at EPICENTER are (i) a diagnosis of an affective or schizophrenia spectrum psychotic disorder as determined by the Structured Clinical Interview for the DSM-IV (SCID [27]), (ii) less than 5 years of frank psychotic symptoms as determined by the Symptom Onset in Schizophrenia inventory (SOS [28]), (iii) being between the ages of 18–35, and (iv) willingness to receive treatment at EPICENTER. The durational criteria for psychotic symptoms (< 5 years) is based on the operational definition of first-episode psychosis outlined by Breitborde and colleagues [29]. Individuals with first-episode psychosis are excluded from EPICENTER if they meet criteria for substance-induced psychosis as determined by the SCID, are unwilling or unable to provide informed consent, or meet criteria for a diagnosis of mental retardation. Caregiving relatives are defined as someone with whom the individual with first-episode psychosis maintains considerable face-to-face contact (≥ 10 hours per week).

Family caregivers do not need to be biological relatives of the individual with first-episode psychosis. It is anticipated that some individuals with first-episode psychosis will have more than one caregiving relative who wishes to participate in the study; hence, we anticipate recruiting ≈ 1.5 familial caregivers for each individual with first-episode psychosis.

Given that the onset of psychosis typically occurs between the ages of 15-35 [median ≈ 22 -23 years] [30], we expect that our cohort of individuals with recent-onset psychosis will be comprised largely of young adults. As noted earlier, due to EPICENTER inclusion criteria, no individuals younger than 18 years old will be included in this study. As the prevalence of psychotic disorders within the United States does not appear to differ across racial or ethnic groups [31], we expect that racial and ethnic distribution of individuals with first-episode psychosis who participate in this study will be consistent with the racial and ethnic distribution of Tucson, Arizona. Per the 2000 U.S. Census data for Tucson, Arizona, this would lead us to expect that the racial distribution of our sample will be 70% White, 4% African American, 2% American Indian, 2% Asian American, <1% Native Hawaiian or other Pacific Islander, 4% multiracial, and 17% other. With regard to ethnicity, we expect that the overall sample will be comprised of 36% Hispanic/Latino individuals and 64% non-Hispanic/Latino individuals. We expect to find a similar ethnic and racial breakdown among the family caregivers who participate in this study.

First-episode psychosis studies have long reported recruiting a preponderance of male subjects [32]. Thus, we expect that our sample of individuals with first-episode psychosis will be largely male ($\approx 70\%$). Conversely, studies of family caregivers of individuals with psychotic disorders have historically recruited a preponderance of female caregivers [33]. As such, we expect that our sample of caregivers will be largely female ($\approx 70\%$).

Number of Participants and Power Analysis

Current recommendations for a priori determination of the number of subjects to include in a study suggest the inclusion of sufficient subjects to maintain adequate statistical power to detect a clinically meaningful effect size [34]. One such measure, Number Needed to Treat (NNT) [35], has been identified as particularly useful in conveying clinical significance and in guiding the design of randomized clinical trials [36]. NNT provides an estimate of the number of individuals who would need to receive a treatment in order to prevent the occurrence of one negative outcome. With regard to family psychoeducation, a recent meta-analysis found that the NNT for this intervention was 8; (95% CI 6-18) [9]. This suggests that this intervention would need to be provided to 8 individuals to prevent one relapse. Although

there is no established criteria for a clinically meaningful reduction in NNT [36], for the current study we defined a clinically meaningful benefit of the MFG and CR condition as an NNT one-half the size of the NNT for MFG alone (i.e., an NNT for MFG and CR = 4). This value (i.e., NNT = 4) falls outside of the 95% confidence interval of the NNT for family psychoeducation alone as reported in a past meta-analysis [9] and is consistent with the NNT value used to determine a priori statistical power for most randomized controlled trials of interventions for mental illnesses [36]. Using these NNT values and the pwr software package [37] developed for the R statistical platform [38], we determined that 17 families (i.e., individual with first-episode psychosis and caregiving relative[s]) would need to be allocated to both the MFG-CR and MFG alone conditions, respectively, to ensure statistical power of 0.80 (i.e., total sample size = 34). To protect against subject attrition, we will recruit an additional 6 families (i.e., $\approx 20\%$ of the total sample size), bringing the total sample size to 40.


Randomization and Treatment Allocation

Treatment allocation for this study is depicted in Figure 1. Upon enrollment in the project, individuals with first-episode psychosis will be randomized to either the MFG and CR condition or the MFG alone condition. Randomization will be completed using a block randomization procedure with blocks of varying sizes.

Interventions

Multifamily Group Psychoeducation

Per the protocol outlined by McFarlane [11], the MFG intervention involves three phases: (i) joining, a process of engaging patients and their key family members, (ii) a psychoeducational workshop, and (iii) multifamily problem-solving sessions. During the joining phase, family members meet with the clinician who will lead the MFG to discuss their ill relative's clinical history, the family's experience and understanding of their ill relative's illness, and family members' concerns and questions with regard to participating in a multifamily group. Concurrent to these sessions with the family, the individual with first-episode psychosis will also complete three individual sessions with the clinician to build rapport and trust in the relationship between the clinician and the individual with first-episode psychosis. Following the completion of the joining phase, family members and clinically stable patients participate in a day-long educational workshop on psychosis which provides an overview of the causes and prognosis of psychotic disorders, current treatments for these disorders, and the ways in which family members may be affected by severe mental illness in the family. Family members are also presented with guidelines for illness management as well as



strategies to maintain family balance and well-being. Following the completion of the psychoeducational workshop, families and their ill relatives begin to participate in bi-weekly multifamily problem-solving sessions. During the problem solving sessions, caregivers and ill relatives identify challenges or problems occurring in their lives and identify possible solutions to these problems through a structured problem-solving activity.

All individuals with first-episode psychosis will participate in the MFG intervention for twelve months. This duration of treatment is consistent with recommendations from the Patient Outcomes Research Team (PORT) convened by the Agency for Health Care Policy and Research and the National Institute of Mental Health [39,40]. Of note, unlike the traditional MFG model, family groups in this study will be run using rolling admissions with families graduating from the group after twelve months of participation.

Cognitive Remediation

Individuals with first-episode psychosis who are randomized to the MFG and CR condition will complete the cognitive remediation program PSSCogRehab [41]. This computerized cognitive remediation program provides participants with training in 4 areas of cognitive functioning: attention, visual-spatial abilities, memory, and problem-solving abilities. Participants initially complete simple tasks in each domain and, once mastered, gradually progress to more difficult tasks. Completion of the

training program occurs once subjects have mastered all of the training tasks. This program has been frequently used in past studies of cognitive remediation in psychotic disorders [42-48], and more recently has been applied specifically among individuals early in the course of a psychotic illness [49,50]. This intervention has been shown to promote improvements in problem-solving among individuals with psychotic disorders [42], and has been administered successfully with other concurrent psychosocial interventions [44].

Primary Outcome Measure

Relapse

Symptomatology among individuals with first-episode psychosis will be assessed using the Positive and Negative Syndrome Scale (PANSS) [51] on a weekly basis during their participation in the study. Based on participants' scores on this measure, the occurrence of a relapse will be determined using the criteria established by Nuechterlein and colleagues [52]. Of note, although the criteria outlined by Nuechterlein and colleagues were designed for use with the Brief Psychiatric Rating Scale (BPRS [53]), the specific items on the BPRS used to determine the occurrence of a relapse using the Nuechterlein criteria (i.e., hallucinations, unusual thought content, and conceptual disorganization) are also included in the PANSS (i.e., hallucinations, delusions, and conceptual disorganization). These shared

items are scored in an identical manner on both measures and each item on BPRS has been shown to be strongly correlated with its comparable item on the PANSS (weighed kappas of 0.65 [good] to 0.86 [excellent]) [54].

Secondary Outcome Measures

Recognizing that recovery from psychotic disorders involves more than just a remission of psychotic symptoms [55], we will also explore the benefit of combining MFG and CR on other outcomes among individuals with first-episode psychosis. These will include social and vocational functioning (Social Functioning Scale: SFS [56]), everyday functioning (brief form of the UCSD Performance-Based Skills Assessment: UPSA [57]), health-related quality of life (RAND 36-Item Health Survey [58]), service utilization (Service Utilization and Resources Form for Schizophrenia: SURF [59]), and independent living status. Independent living status will be assessed using the methodology outlined by Palmer et al. [60]. Per this methodology, subjects' living status will be rated on a 4-point scale ranging from (1) 'totally dependent' (i.e., living in a facility with 24-hour clinical care) to (4) 'independent' (i.e., living alone or with a partner who provides a level of support consistent in typical cohabitation relationships). These measures will be administered when subjects enroll in the study and again after the completion of 12 months of MFG.

Additionally, to replicate findings linking participation in CR to improved cognitive functioning among individuals with psychotic disorders [26], individuals with first-episode will complete the consensus cognitive battery developed by the National Institute of Mental Health's Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative [61]. Of note, this battery does include a specific assessment of problem-solving skills (i.e., the mazes subtest from the Neuropsychological Assessment Battery [62]). Participants in the MFG and CR condition will complete the MATRICS battery three times over the course of the study: (i) at enrollment; (ii) upon completion of CR intervention, and (iii) upon completion of 12 months of the MFG intervention. Individuals randomized to the MFG alone condition will complete the MATRICS battery three times over the course of the study: (i) at enrollment, (ii) at 10 weeks, and (iii) upon completion of 12 months of the MFG intervention.

Caregiving relatives of individuals with psychotic disorders have also been shown to experience a reduction in caregiver burden and psychological distress (e.g., depression and anxiety) after participation in family psychoeducation [63,64]. Thus, we plan to conduct additional secondary analyses to examine whether caregivers whose ill relatives are in the MFG and CR group

experience greater benefits in these areas as compared to caregivers whose ill relatives are in the MFG alone condition. Caregiver burden will be assessed using the Burden Assessment Scale [BAS] [65], and depression and anxiety will be assessed using the Beck Depression Inventory [BDI] [66] and Beck Anxiety Inventory [BAI] [67], respectively. These measures will be administered upon enrollment to the study and after completion of 12 months of MFG.

Proposed Analyses

All analyses will be completed using an "intention-to-treat" principle [68] such that data from all subjects will be included in the analysis regardless of their level of adherence to the interventions over the course of the study.

The association between intervention condition (i.e., MFG and CR vs. MFG alone) and relapse will be examined using a chi-square. However, in situations in which the requirements for this analysis are violated (e.g., expected value of any cell ≤ 5), Fisher's exact probability test [69] with the continuity correction proposed by Overall [70] will be used instead.

Per the recommendations outlined by Vickers and Altman [71], the association between intervention condition (i.e., MFG and CR vs. MFG alone) and continuous secondary outcome measures (e.g., caregiver burden and social functioning scores) will be examined using an analysis of covariance with participants' baseline scores on the secondary outcome measure included as a covariate. With regard to the association between intervention condition and categorical secondary outcome measures (e.g., employed vs. unemployed), a chi-square analysis will be used. However, in situations in which the requirements for this analysis are violated, Fisher's exact probability test [69] with the continuity correction proposed by Overall [70] will be used instead.

Discussion

Multifamily group psychoeducation is an evidence-based and cost-effective treatment for psychotic disorders [13,14,72]. However, like all psychosocial interventions, certain individuals who participate in MFG will still go on to experience negative health outcomes. Cognitive remediation offers the possibility of ameliorating a specific deficit (i.e., a deficit in cognitive functioning) that often accompanies psychotic symptoms and may restrict the magnitude of the clinical benefits derived from MFG.

Acknowledgements

This project is supported by a grant from the Institute for Mental Health Research (2010-BN-07 to NJKB) and funds from the University of Arizona, Department of Psychiatry (to NJKB).

Author details

¹Department of Psychiatry, University of Arizona, 1501 N. Campbell Ave., PO Box 245002, Tucson, AZ, 85724-5002, USA. ²Department of Psychiatry, University Physicians Hospital, 2800 E. Ajo Way, Tucson, Arizona, 85713, USA. ³Department of Psychiatry, University of Rochester Medical Center, 601 Elmwood Ave., Rochester, New York, 14642, USA. ⁴Department of Psychiatry, Maine Medical Center, 295 Park Ave., Portland, Maine, 04102, USA.

Authors' contributions

Study concept and design: NJKB; Protocol management: NM-D, RP; Drafting of the manuscript: NJKB; Critical Revision of the manuscript: FAM, NM-D, RP, SB, WM. All authors approved the final version of this manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 12 December 2010 Accepted: 12 January 2011

Published: 12 January 2011

References

1. Crumlish N, Whitty P, Clarke M, Browne S, Kamali M, Gervin M, McTigue O, Kinsella A, Waddington JL, Larkin C, O'Callaghan E: **Beyond the critical period: Longitudinal study of 8-year outcome in first-episode non-affective psychosis.** *British Journal of Psychiatry* 2009, **194**.
2. Lieberman JA, Perkins D, Belger A, Chakos M, Jarskog F, Boteva K, Gilmore J: **The early stages of schizophrenia: Speculations on pathogenesis, pathophysiology, and therapeutic approaches.** *Biological Psychiatry* 2001, **50**:884-897.
3. McGlashan TH: **A selective review of recent North American follow-up studies on schizophrenia.** *Schizophrenia Bulletin* 1998, **14**:515-542.
4. Birchwood M: **Early intervention in psychosis: The critical period.** In *The Recognition and Management of Early Psychosis: A Preventative Approach*. Edited by: Jackson HJ. Port Chester, NY: Cambridge University Press; 1999:226-264.
5. Birchwood M, Fiorillo A: **The critical period for early intervention.** *American Journal of Psychiatric Rehabilitation* 2000, **4**:182-198.
6. Birchwood M, Todd P, Jackson C: **Early intervention in psychosis: The critical period hypothesis.** *British Journal of Psychiatry* 1998, **172**:53-59.
7. Reading B, Birchwood M: **Early intervention in psychosis: Rationale and evidence for effectiveness.** *Disease Management and Health Outcomes* 2005, **13**:53-63.
8. McFarlane WR, Dixon L, Lukens E, Lucksted A: **Family psychoeducation and schizophrenia: A review of the literature.** *Journal of Marital and Family Therapy* 2003, **29**:223-245.
9. Pilling S, Bebbington P, Kuipers E, Garety P, Geddes J, Orbach G, Morgan C: **Psychological treatments in schizophrenia: I. Meta-analysis of family intervention and cognitive behaviour therapy.** *Psychological Medicine* 2002, **32**:763-782.
10. Pitschel-Walz G, Leucht S, Bauml J, Kissling W, Engel RR: **The effect of family interventions on relapse and rehospitalization in schizophrenia—a meta-analysis.** *Schizophrenia Bulletin* 2001, **27**:73-92.
11. McFarlane WR: *Multifamily groups in the treatment of severe psychiatric disorders* New York: Guilford Press; 2002.
12. Goldstein MJ: **Psycho-education and family treatment related to the phase of a psychotic disorder.** *International Clinical Psychopharmacology* 1996, **11**(suppl 2):77-83.
13. McFarlane WR, Lukens E, Link B, Dushay R, Deakins SA, Newmark M, Dunne EJ, Horen B, Toran J: **Multiple-family groups and psychoeducation in the treatment of schizophrenia.** *Archives of General Psychiatry* 1995, **52**:679-687.
14. McFarlane WR, Link B, Dushay R, Marchal J, Crilly J: **Psychoeducational multiple family groups: Four-year relapse outcome in schizophrenia.** *Family Process* 1995, **34**:127-144.
15. Bertelsen M, Jeppesen P, Petersen L, Thorup A, Øhlenschläger J, Ie Quach P, Christensen TO, Kirrup G, Jørgensen P, Nordentoft M: **Five-year follow-up of a randomized multicenter trial of intensive intervention vs standard treatment for patients with a first episode of psychotic illness: The OPUS study.** *Archives of General Psychiatry* 2008, **65**:762-771.
16. Fjell A, Thorsen GRB, Friis S, Johannessen JO, Larsen TK, Lie K, Lyse HG, Melle I, Simonsen E, Smeby NA, Øxnevad AL, McFarlane WR, Vaglum P, McGlashan T: **Multifamily group treatment in a program for patients with first-episode psychosis: Experiences from the TIPS project.** *Psychiatric Services* 2007, **58**:171-173.
17. Kuipers E: **Psychological therapies for schizophrenia: Family and cognitive interventions.** *Psychiatric Times* 2007, **29**:1-8.
18. Green MF, Kern RF, Braff DL, Mintz JL: **Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the "right stuff"?** *Schizophrenia Bulletin* 2000, **26**:119-136.
19. Green MF: **Cognitive impairment and functional outcome in schizophrenia and bipolar disorder.** *Journal of Clinical Psychiatry* 2006, **67**(suppl 9):3-8.
20. Heinrichs RW, Zakzanis KK: **Neurocognitive deficit in schizophrenia: A qualitative review of the evidence.** *Neuropsychology* 1998, **12**:426-445.
21. Gold JM: **Cognitive deficits as treatment targets in schizophrenia.** *Schizophrenia Research* 2004, **72**:21-28.
22. Gold JM, Green MF: **Neurocognition in schizophrenia.** In *Comprehensive Textbook of Psychiatry*. Edited by: Sadock VA. Maryland: Lippincott, Williams, Wilkins.
23. Green MF: **What are the functional consequences of neurocognitive deficits in schizophrenia.** *American Journal of Psychiatry* 1996, **153**:321-330.
24. Browne M, Peer J, Spaulding W: **Best practice guidelines for cognitive rehabilitation for people with serious mental illness.** [http://www.bhmr.org/guidelines/spaulding.pdf].
25. APA/CAAP Task Force on Serious Mental Illness and Severe Emotional Disturbance: **Training grid outlining best practices for people with serious mental illness.** 2005.
26. McGurk SR, Twamley EW, Sitzer DI, McHugo GJ, Mueser KT: **A meta-analysis of cognitive remediation in schizophrenia.** *American Journal of Psychiatry* 2007, **164**:1791-1802.
27. First MB, Spitzer RL, Gibbon M, Williams JBW: *Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition with Psychotic Screen (SCID-I/P W/PSY SCREEN)* New York: Biometrics Research, New York State Psychiatric Institute; 2002.
28. Perkins DO, Leserman J, Jarskog LF, Graham K, Kazmer J, Lieberman JA: **Characterizing and dating the onset of symptoms in psychotic illness.** *Schizophrenia Research* 2002, **44**:1-10.
29. Breitborde NJK, Srihari VH, Woods SW: **Review of the operational definition of first-episode psychosis.** *Early Intervention in Psychiatry* 2009, **3**:259-265.
30. Kessler RC, Amminger GP, Aguilar-Gaxiola S, Alonso J, Lee S, Üstün TB: **Age of onset of mental disorders: A review of recent literature.** *Current Opinion in Psychiatry* 2007, **20**:359-364.
31. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS: **Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Study.** *Archives of General Psychiatry* 1994, **51**:8-19.
32. Iacono WG, Beiser M: **Where are the women in first-episode studies of schizophrenia.** *Schizophrenia Bulletin* 1992, **18**:471-280.
33. Cook JA: **Who "mothers" the chronically mentally ill?** *Family Relations* 1988, **37**:42-49.
34. Lenth RV: **Some practical guidelines for effective sample size determination.** *American Statistician* 2001, **55**:187-193.
35. Laupacis A, Sackett DL, Roberts RS: **An assessment of clinically useful measures of the consequence of treatment.** *New England Journal of Medicine* 1988, **318**:1728-1733.
36. Kraemer HC, Kupfer DJ: **Size of treatment effects and their importance to clinical research and practice.** *Biological Psychiatry* 2006, **59**:990-996.
37. Champely S: **pwr: Basic functions for power analysis.** 2007.
38. R Development Core Team: *R: A language and environment for statistical computing* Vienna, Austria: R Foundation for Statistical Computing; 2008.
39. Lehman AF, Steinwachs DM, the Co-Investigators of the PORT Project: **At issue: Translating research into practice: The Schizophrenia Patient Outcomes Research Treatment Recommendations.** *Schizophrenia Bulletin* 1998, **24**:1-10.
40. Lehman AF, Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB, Goldberg R, Green-Paden LD, Tenhula WN, Boerescu D, Tek C, Sandson N, Steinwachs DM: **The Schizophrenia Patient Outcomes Research Team (PORT): Updated treatment recommendations 2003.** *Schizophrenia Bulletin* 2004, **30**:193-217.
41. Bracy O: *PSS CogRehab Software, Version 95* Indianapolis, IN: Psychological Software Services, Inc; 1995.

42. Kurtz MM, Seltzer JC, Shagan DS, Thime WR, Wexler BE: **Computer-assisted cognitive remediation in schizophrenia: What is the active ingredient?** *Schizophrenia Research* 2007, **89**:251-260.
43. Greig TC, Zito W, Wexler BE, Fiszdon J, Bell MD: **Improved cognitive function in schizophrenia after one year of cognitive training and vocational services.** *Schizophrenia Research* 2007, **96**:156-161.
44. Bell M, Bryson G, Greig T, Corcoran C, Wexler BE: **Neurocognitive enhancement therapy with work therapy: Effects on neuropsychological test performance.** *Archives of General Psychiatry* 2001, **58**:763-768.
45. Fiszdon JM, Bryson GJ, Wexler BE, Bell MD: **Durability of cognitive remediation training in schizophrenia: Performance on two memory tasks at 6-month and 12-month follow-up.** *Psychiatry Research* 2004, **125**:1-7.
46. Fiszdon JM, Cardenas AS, Bryson GJ, Bell MD: **Predictors of remediation success on a trained memory task.** *Journal of Nervous and Mental Disease* 2005, **193**:602-608.
47. Fiszdon JM, Choi J, Bryson GJ, Bell MD: **Impact of intellectual status on response to cognitive task training in patients with schizophrenia.** *Schizophrenia Research* 2006, **87**:261-269.
48. Hogarty GE, Flesher S, Ulrich R, Carter M, Greenwald D, Pogue-Geile M, Keshavan M, Cooley S, DiBarry AL, Garrett A, Parepally H, Zoretich R: **Cognitive enhancement therapy for schizophrenia. Effects of a 2-year randomized trial on cognition and behavior.** *Archives of General Psychiatry* 2004, **61**:866-876.
49. Eack SM, Greenwald DP, Hogarty SS, Cooley SJ, DiBarry AL, Montrose DM, Keshavan MS: **Cognitive enhancement therapy for early-course schizophrenia: Effects of a two-year randomized controlled trial.** *Psychiatric Services* 2009, **60**:1468-1476.
50. Eack SM, Hogarty GE, Greenwald DP, Hogarty SS, Keshavan MS: **Cognitive enhancement therapy improves emotional intelligence in early course schizophrenia: Preliminary effects.** *Schizophrenia Research* 2007, **89**:308-311.
51. Kay SR, Fiszbein A, Opler LA: **The positive and negative syndrome scale for schizophrenia.** *Schizophrenia Bulletin* 1987, **10**:288-298.
52. Nuechterlein KH, Miklowitz DJ, Ventura J, Gitlin MJ, Stoddard M, Lukoff D: **Classifying episodes in schizophrenia and bipolar disorder: Criteria for relapse and remission applied to recent-onset samples.** *Psychiatry Research* 2006, **144**:153-166.
53. Overall JE, Gorham DR: **The Brief Psychiatric Rating Scale.** *Psychological Reports* 1962, **10**:799-812.
54. Bell M, Milstein R, Beam-Goulet J, Lysaker P, Cicchetti D: **The positive and negative syndrome scale and the brief psychiatric rating scale: Reliability, comparability, and predictive validity.** *Journal of Nervous and Mental Disease* 1992, **180**:723-728.
55. Liberman RP, Kopelowicz A, Ventura J, Gutkind D: **Operational criteria and factors related to recovery from schizophrenia.** *International Review of Psychiatry* 2002, **14**:256-272.
56. Birchwood M, Smith J, Cochrane R, Wetton S, Copestake S: **The social functioning scale: The development and validation of a new scale for social adjustment for use in family intervention programmes with schizophrenic patients.** *British Journal of Psychiatry* 1990, **157**:853-859.
57. Mausbach BT, Harvey PD, Goldman SR, Jeste DV, Patterson TL: **Development of a brief scale of everyday functioning in persons with serious mental illness.** *Schizophrenia Bulletin* 2007, **33**:1364-1372.
58. Hays RD, Sherbourne CD, Mazel RM: **The RAND 36-Item Health Survey.** *Health Economics* 1993, **2**:217-227.
59. Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RSE, Swartz M, Perkins DO, Hsiao JK, Lieberman JA: **Cost-effectiveness of second generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.** *American Journal of Psychiatry* 2007, **163**:2080-2089.
60. Palmer BW, Heaton RK, Gladsjo JA, Evans JD, Patterson TL, Golshan S, Jeste DV: **Heterogeneity in functional status among older outpatients with schizophrenia: Employment history, living situations, and driving.** *Schizophrenia Research* 2002, **55**:205-215.
61. Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, Fenton WS, Freese FJ, Gold JM, Goldberg T, Heaton RK, Keefe RSE, Kraemer H, Mesholam-Gately R, Seidman LJ, Stover E, Weinberger DR, Young AS, Zalcman S, Marder SR: **The MATRICS consensus cognitive battery, part 1: Test selection, reliability, and validity.** *American Journal of Psychiatry* 2008, **165**:203-213.
62. White T, Stern RA: *Neuropsychological Assessment Battery: Psychometric and technical manual* Lutz, FL: Psychological Assessment Resources, Inc; 2003.
63. Cuijpers P: **The effects of family interventions on relatives' burden: A meta-analysis.** *Journal of Mental Health* 1999, **8**:275-285.
64. Hazel NA, McDonnell MG, Short RA, Berry CM, Voss WD, Rodgers ML, Dyck DG: **Impact of multiple-family groups for outpatients with schizophrenia on caregivers' distress and resources.** *Psychiatric Services* 2004, **55**:35-41.
65. Reinhard SC, Gubman GD, Horwitz AV, Minsky S: **Burden Assessment Scale for families of the seriously mentally ill.** *Evaluation and Program Planning* 1994, **17**:261-269.
66. Beck AT, Steer RA, Ball R, Ranieri WF: **Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients.** *Journal of Personality Assessment* 1996, **67**:588-597.
67. Beck AT, Epstein N, Brown G, Steer RA: **An inventory for measuring clinical anxiety: Psychometric properties.** *Journal of Consulting and Clinical Psychology* 1988, **56**:893-897.
68. Montori VM, Guyatt GH: **Intention-to-treat principle.** *Canadian Medical Association Journal* 2001, **165**:1339-1341.
69. Fisher RA: *Statistical methods for research workers* New York: Hafner; 1970.
70. Overall JE: **Continuity correction for Fisher's exact probability test.** *Journal of Educational Statistics* 1980, **5**:177-190.
71. Vickers AJ, Altman DG: **Analysing controlled trials with baseline and follow up measurements.** *BMJ* 2001, **323**:1123-1124.
72. Breitborde NJK, Woods SW, Srihari VH: **Multifamily psychoeducation for first-episode psychosis: A cost-effectiveness analysis.** *Psychiatric Services* 2009, **60**:1477-1483.

Pre-publication history

The pre-publication history for this paper can be accessed here:
<http://www.biomedcentral.com/1471-244X/11/9/prepub>

doi:10.1186/1471-244X-11-9

Cite this article as: Breitborde et al.: Multifamily Group Psychoeducation and Cognitive Remediation for First-Episode Psychosis: A Randomized Controlled Trial. *BMC Psychiatry* 2011 **11**:9.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

